270 results on '"Chulanov, Vladimir"'
Search Results
2. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
3. Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
4. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
5. Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus
6. Technological aspects of manufacturing and analytical control of biological nanoparticles
7. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
8. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
9. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
10. TOP-400 Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection
11. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
12. WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta
13. LBP-029 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
14. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial
15. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
16. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
17. The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution.
18. May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?
19. m6A Methylation in Regulation of Antiviral Innate Immunity
20. Fibrosing cholestatic hepatitis as a variant of the course of hepatotropic viruses’ infection
21. Epidemiology, course and predictors of long-term COVID infection (long COVID): A review
22. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment.
23. Previously Diagnosed HIV Infection in Patients with COVID-19 and Advanced HIV Disease Improves Their Survival
24. Nanomedicine for increasing the oral bioavailability of cancer treatments
25. Genetic Diversity of the Hepatitis B Virus and Its Epidemiological Significance
26. Epidemiology of Hepatitis B
27. m 6 A Methylation in Regulation of Antiviral Innate Immunity.
28. The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic
29. P134 Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta: results from an interim analysis of a phase 3 randomized study
30. Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
31. Dead Cas Systems: Types, Principles, and Applications
32. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
33. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus
34. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
35. Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
36. Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
37. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & HepatologyCommission update
38. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
39. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9
40. Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19
41. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics
42. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9
43. Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks
44. Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study
45. Predictive model of COVID-19 outcomes in patients with advanced HIV infection
46. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
47. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle-Mimetic Nanovesicles Loaded with Chemotherapeutics
48. Genetic Diversity and Possible Origins of the Hepatitis B Virus in Siberian Natives
49. Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region
50. WED-158 - Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.